Examining the efficacy of adjunctive aripiprazole in major depressive disorder: a pooled analysis of 2 studies
Michael E Thase, Madhukar H Trivedi, J Craig Nelson, Maurizio Fava, Rene Swanink, Quynh-Van Tran, Andrei Pikalov, Huyuan Yang, Berit X Carlson, Ronald N Marcus, Robert M Berman, Michael E Thase, Madhukar H Trivedi, J Craig Nelson, Maurizio Fava, Rene Swanink, Quynh-Van Tran, Andrei Pikalov, Huyuan Yang, Berit X Carlson, Ronald N Marcus, Robert M Berman
Abstract
Background: Patients with major depressive disorder (MDD) who fail to achieve complete remission with antidepressant therapy may benefit from augmentation therapy with an atypical antipsychotic.
Method: A pooled analysis was performed on 2 identical 14-week studies (8-week prospective antidepressant therapy treatment phase followed by 6-week randomized double-blind phase) evaluating the efficacy of adjunctive aripiprazole (2-20 mg/day) in DSM-IV-TR-defined MDD patients with an inadequate response to antidepressant therapy. Primary efficacy endpoint was the mean change in Montgomery-Asberg Depression Rating Scale (MADRS) total score from end of the prospective phase (week 8) to end of randomized phase (week 14, last observation carried forward). Subgroup analyses were performed. The key secondary endpoint was mean change in Sheehan Disability Scale (SDS) mean score.
Results: At endpoint, mean change in MADRS total score was significantly greater with adjunctive aripiprazole (-8.7) than with adjunctive placebo (-5.7; p < .001). Except for a differential treatment-by-sex interaction, change in MADRS total scores were consistently greater with adjunctive aripiprazole than with adjunctive placebo, regardless of race, age, episode duration, prior antidepressant therapy response, number of historical treatment failures, severity of depressive symptoms, and antidepressant. At endpoint, MADRS remission rates were significantly greater with adjunctive aripiprazole than with placebo (25.7% vs. 15.4%; p < .001). Adjunctive aripiprazole also demonstrated significantly greater improvements in mean change from baseline in SDS total score than adjunctive placebo (-1.2 vs. -0.6; p = .001).
Conclusion: Augmentation of antidepressant therapy with the atypical antipsychotic aripiprazole resulted in significant efficacy benefits across a range of subgroups of patients with MDD. Further study of a treatment-by-sex interaction is needed.
Trial registration: www.clinicaltrials.gov Identifiers: NCT00095823 and NCT00095758.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2644484/bin/pcc10440f01.jpg)
Figure 2
Mean Change in Sheehan Disability…
Figure 2
Mean Change in Sheehan Disability Scale (SDS) Mean Scores and Family, Social, and…
Figure 3
Remission a Rates in the…
Figure 3
Remission a Rates in the Adjunctive Placebo and Adjunctive Aripiprazole Groups During Double-Blind…
- Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features.Trivedi MH, Thase ME, Fava M, Nelson CJ, Yang H, Qi Y, Tran QV, Pikalov A, Carlson BX, Marcus RN, Berman RM. Trivedi MH, et al. J Clin Psychiatry. 2008 Dec;69(12):1928-36. Epub 2008 Dec 2. J Clin Psychiatry. 2008. PMID: 19192475 Clinical Trial.
- The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, Khan A. Berman RM, et al. J Clin Psychiatry. 2007 Jun;68(6):843-53. doi: 10.4088/jcp.v68n0604. J Clin Psychiatry. 2007. PMID: 17592907 Clinical Trial.
- Effects of adjunctive aripiprazole on sexual functioning in patients with major depressive disorder and an inadequate response to standard antidepressant monotherapy: a post hoc analysis of 3 randomized, double-blind, placebo-controlled studies.Fava M, Dording CM, Baker RA, Mankoski R, Tran QV, Forbes RA, Eudicone JM, Owen R, Berman RM. Fava M, et al. Prim Care Companion CNS Disord. 2011;13(1):PCC.10m00994. doi: 10.4088/PCC.10m00994gre. Prim Care Companion CNS Disord. 2011. PMID: 21731833 Free PMC article.
- Aripiprazole: in major depressive disorder.Weber J, Lyseng-Williamson KA, Scott LJ. Weber J, et al. CNS Drugs. 2008;22(10):807-13. doi: 10.2165/00023210-200822100-00002. CNS Drugs. 2008. PMID: 18788833 Review.
- Novel Augmentation Strategies in Major Depression.Martiny K. Martiny K. Dan Med J. 2017 Apr;64(4):B5338. Dan Med J. 2017. PMID: 28385173 Review.
- Major Depressive Disorder (MDD) and Schizophrenia- Addressing Unmet Needs With Partial Agonists at the D2 Receptor: A Review.Mallet J, Gorwood P, Le Strat Y, Dubertret C. Mallet J, et al. Int J Neuropsychopharmacol. 2019 Oct 1;22(10):651-664. doi: 10.1093/ijnp/pyz043. Int J Neuropsychopharmacol. 2019. PMID: 31406978 Free PMC article. Review.
- Functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studies.Weiller E, Weiss C, Watling CP, Edge C, Hobart M, Eriksson H, Fava M. Weiller E, et al. Neuropsychiatr Dis Treat. 2017 Dec 29;14:103-115. doi: 10.2147/NDT.S146840. eCollection 2018. Neuropsychiatr Dis Treat. 2017. PMID: 29343962 Free PMC article. Review.
- Combining moderators to identify clinical profiles of patients who will, and will not, benefit from aripiprazole augmentation for treatment resistant late-life major depressive disorder.Smagula SF, Wallace ML, Anderson SJ, Karp JF, Lenze EJ, Mulsant BH, Butters MA, Blumberger DM, Diniz BS, Lotrich FE, Dew MA, Reynolds CF 3rd. Smagula SF, et al. J Psychiatr Res. 2016 Oct;81:112-8. doi: 10.1016/j.jpsychires.2016.07.005. Epub 2016 Jul 7. J Psychiatr Res. 2016. PMID: 27438687 Free PMC article.
- Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort.Lam RW, Milev R, Rotzinger S, Andreazza AC, Blier P, Brenner C, Daskalakis ZJ, Dharsee M, Downar J, Evans KR, Farzan F, Foster JA, Frey BN, Geraci J, Giacobbe P, Feilotter HE, Hall GB, Harkness KL, Hassel S, Ismail Z, Leri F, Liotti M, MacQueen GM, McAndrews MP, Minuzzi L, Müller DJ, Parikh SV, Placenza FM, Quilty LC, Ravindran AV, Salomons TV, Soares CN, Strother SC, Turecki G, Vaccarino AL, Vila-Rodriguez F, Kennedy SH; CAN-BIND Investigator Team. Lam RW, et al. BMC Psychiatry. 2016 Apr 16;16:105. doi: 10.1186/s12888-016-0785-x. BMC Psychiatry. 2016. PMID: 27084692 Free PMC article.
- Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology.Goodwin GM, Haddad PM, Ferrier IN, Aronson JK, Barnes T, Cipriani A, Coghill DR, Fazel S, Geddes JR, Grunze H, Holmes EA, Howes O, Hudson S, Hunt N, Jones I, Macmillan IC, McAllister-Williams H, Miklowitz DR, Morriss R, Munafò M, Paton C, Saharkian BJ, Saunders K, Sinclair J, Taylor D, Vieta E, Young AH. Goodwin GM, et al. J Psychopharmacol. 2016 Jun;30(6):495-553. doi: 10.1177/0269881116636545. Epub 2016 Mar 15. J Psychopharmacol. 2016. PMID: 26979387 Free PMC article.
- ClinicalTrials.gov/NCT00095823
- ClinicalTrials.gov/NCT00095758
- Full Text Sources
- Medical
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2644484/bin/pcc10440f02.jpg)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2644484/bin/pcc10440f03.jpg)
Source: PubMed